These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 31152966)
1. Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study. Buard G; Giovannelli J; Outteryck O; Hadhoum N; Lannoy J; Vermersch P; Zéphir H Mult Scler Relat Disord; 2019 Aug; 33():39-43. PubMed ID: 31152966 [No Abstract] [Full Text] [Related]
2. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis. Soini E; Joutseno J; Sumelahti ML Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373 [TBL] [Abstract][Full Text] [Related]
3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
4. Spotlight on teriflunomide. Tallantyre E; Evangelou N; Constantinescu CS Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502 [TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A; J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931 [TBL] [Abstract][Full Text] [Related]
6. Teriflunomide for the treatment of multiple sclerosis. Oh J; O'Connor PW Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212 [TBL] [Abstract][Full Text] [Related]